Capacity, Patent Cliff and Buyout
Capacity:
The key to understanding where Elite Pharmaceuticals (ELTP) is heading lies not in a buyout or Nasdaq uplisting, but in understanding its manufacturing capacity.
Since the last conference call, I have talked about ELTP's production capacity.
If you were working a minimum-wage job, would you buy a garage for a car you don't even own? Obviously not, and your family (or shareholders) would think you were being foolish.
In the Q4 2026 call, Nasrat said that he turned down offers from third-party companies seeking to use Elite's production lines. At the time, I pointed out that ELTP rejected this contract work because they knew they would need that capacity for their own products. During that call, Nasrat stated:
"On manufacturing shifts, we run a single shift on two lines and that takes care of our needs. Huge opportunity for growth if we double or triple capacity."
Fast-forward to the Q1 2027 call, when an investor asked: If Elite is currently running only a single shift, why is an additional facility expansion necessary?
Nasrat said:
"It is true that we're running only one shift right now. However, you set up your facility for the future. [...] In order for us to have a viable manufacturing facility, we need to take over a warehouse in one of the buildings next to us, revamp it and make it fit for pharmaceuticals, and then put equipment in it, and then qualify the equipment. And that process takes about 2 years."
Expanding pharmaceutical production capacity costs millions, and no one buys a garage without having a car.
Patent Cliff:
Nasrat also said in Q1 2027:
"Other products that are perpetual. We have 25 million to 50 million diabetics in America. There are excellent diabetic products that are coming off patent. Our hat is in the ring, and we are very close to 3 of the formulations. So having that as a product that is ongoing, this is not something that's seasonal. This is not something you take once in a while."
My reading: Between 2025 and 2030/32, hundreds of billions of dollars worth of drug revenues will be exposed to loss of exclusivity. This period is also referred to as the "patent cliff," and I quote: "However, 2026 marks the start of a particularly pronounced cliff, with key patents on billion-dollar drugs set to expire. The US market alone is projected to lose more than $230 billion in revenue between 2025 and 2030." - Source: Drug Discovery News
Link: https://www.drugdiscoverynews.com/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019
Some of you know that Nasrat was working for Actavis. Actavis generics was a company that manufactured obv generics, and it was bought out by Teva in 2016.
The last major patent cliff was between 2011 and 2016. Guess who profited from it? Actavis.
In 2011, Actavis had revenue of $2.5 billion.
In 2016, the last year of the patent cliff, it was around $6 billion.
After doing some research, I come to the conclusion that Actavis indeed benefited and profited significantly from the patent cliff.
Buyout:
The patent cliff is hell for Big Pharma: they are losing revenues and need to replace those revenues with new drugs.
In this scenario, Big Pharma, in order to avoid losing revenues, starts buying companies. Some of them are generic companies, like Teva did with Actavis, not because Teva loved Actavis, but because Teva needed to protect its market share.
So the patent cliff can indeed make ELTP more valuable, or at least make Big Pharma more interested in it, and with that we go back to capacity.
If you are a Big Pharma company and you see that ELTP is increasing its capacity and that ELTP will benefit from the patent cliff, which could reduce your market share, wouldn't you buy ELTP?
To wrap it up:
- ELTP is focused on expansion, not survival: ELTP is expanding its manufacturing facilities for future production, which translates to substantially higher top-line revenues in the coming years, and they will need that capacity within the next 2 years.
- The insight into the facility expansion is the best signal that we have about the future of the company.
- The patent cliff alone will boost ELTP and its pipeline.
- The patent cliff, together with the expansion in manufacturing capacity, will put ELTP on the radar of Big Pharma for a potential buyout